Understand the source comparison
Comparison: GHRP-2 vs Other Growth Hormone Secretagogues
GHRP-2 (Glow Stack) 60–90 minutes 20–30 minutes post-injection 2–3× daily for pulsatile effect Ghrelin receptor (GHS-R1a) agonist with moderate ghrelin-like activity Best for researchers prioritising natural pulsatile rhythm. Short half-life allows precise tim
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-2 (Glow Stack)
- 60–90 minutes
- 20–30 minutes post-injection
- 2–3× daily for pulsatile effect
- Ghrelin receptor (GHS-R1a) agonist with moderate ghrelin-like activity
- Best for researchers prioritising natural pulsatile rhythm. Short half-life allows precise timing around circadian peaks without sustained receptor occupancy
- CJC-1295 (no DAC)
- 30 minutes
- 60–90 minutes post-injection
- 2–3× daily, often stacked with GHRP-2
- Growth hormone-releasing hormone (GHRH) receptor agonist
- Extremely short half-life requires co-administration with a GHRP for synergistic effect. Not viable as monotherapy
- CJC-1295 DAC
- 6–8 days
- Sustained elevation over 7–10 days
- Once weekly
- GHRH receptor with albumin binding for extended release
- Long half-life eliminates pulsatility. Creates sustained GH elevation that can trigger negative feedback and blunt natural secretion over time
- Ipamorelin
- 2 hours
- 30–45 minutes post-injection
- 2–3× daily
- Highly selective GHS-R1a agonist with minimal ghrelin-like effects
- Slightly longer half-life than GHRP-2 with lower appetite stimulation. Preferred when ghrelin side effects are undesirable
- MK-677 (Ibutamoren)
- 4–6 hours (oral bioavailability)
- 90–120 minutes post-dose
- Once daily (oral administration)
- GHS-R1a agonist, orally active
- Oral convenience but sustained receptor activation reduces pulsatility. Appetite stimulation significantly higher than injectable GHRPs
- The half-life of Glow Stack positions it in the middle ground. Short enough to allow pulsatile protocols but long enough that you're not injecting every 90 minutes to maintain effect. Researchers seeking convenience often gravitate toward MK-677 for its oral administration and longer duration, but that comes at the cost of reduced physiological rhythm and increased ghrelin-mediated side effects like persistent hunger and potential insulin resistance over extended use.